TIBER CREEK GROUP

Lobbying for JAZZ PHARMACEUTICALS · â€‹Biopharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $50,000.00 income · posted Jul 18, 2025

Lobbying activity 3

Health Issues

Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxifying hemp.

Medical/Disease Research/Clinical Labs

Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.

Budget/Appropriations

Appropriations issues related to House Ag/FDA Appropriations pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products; Ag/ FDA amendment - technical correction to the 2026 Ag/ FDA appropriations bill related to hemp; Issues related to intoxifying hemp products.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.